Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 10Unknown 2Recruiting 2Terminated 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 1Adenoma 1

Interventions

pembrolizumab 439Carboplatin 322Nivolumab 298Cyclophosphamide 286Specimen Handling 271Magnetic Resonance Spectroscopy 259Cisplatin 250Paclitaxel 249Radiotherapy 230Dexamethasone 184Biopsy 182Gemcitabine 180durvalumab 171atezolizumab 152Doxorubicin 141Rituximab 138Lenalidomide 136Ipilimumab 134Docetaxel 132Bevacizumab 132Radiation 121Capecitabine 120Oxaliplatin 116Etoposide 116Radiosurgery 113Fluorouracil 112Pemetrexed 109fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cabergoline × Clear all
NCT02288962 2025-06-08

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

St. Olavs Hospital

Phase 3 Active not recruiting
60 enrolled
Endocrine

Adenoma, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡